Edwards Lifesciences Wins FDA Nod for AUTUS Pediatric Pulmonary Valve

  • FDA approved Edwards Lifesciences' AUTUS Size-Adjustable Valve for pediatric pulmonary valve replacement on October 1, 2026.
  • The valve is the first FDA-approved surgical pulmonary valve designed for pediatric anatomy, expandable via minimally invasive procedures.
  • Pivotal study showed 100% of patients free from device-related complications through 30 days and consistent outcomes through one year.
  • AUTUS valve previously received FDA Breakthrough Device designation for addressing unmet needs in congenital heart disease.

Edwards Lifesciences' AUTUS valve approval addresses a critical gap in pediatric congenital heart disease treatment, where patients often require multiple surgeries as they grow. This approval strengthens Edwards' leadership in structural heart innovation, particularly in the congenital heart space. The company's focus on long-term patient care aligns with broader industry trends toward minimally invasive, adaptable solutions for complex conditions.

Market Adoption
How quickly congenital heart teams integrate AUTUS into treatment protocols, given its potential to reduce repeat surgeries.
Long-Term Efficacy
Whether the valve's expandability will sustain favorable outcomes over the 10-year follow-up period.
Competitive Dynamics
The pace at which competitors develop similar size-adjustable valves for pediatric patients.